Recently, incretin therapy has attracted increasing attention because of its potential use in tissue-protective therapy. Neuron-derived orphan receptor 1 (NOR1) is a nuclear orphan receptor that regulates vascular smooth muscle cell (VSMC) proliferation. In the present study, we investigated the vascular-protective effect of Exendin-4 (Ex-4), a glucagon-like peptide-1 receptor agonist, by inhibiting NOR1 expression in VSMCs.
of life and mortality by preventing the occurrence and progression of vascular complications. Therefore, it is important to investigate the vascular-protective effects of anti-diabetic agents.
Incretin therapy, which includes glucagon-like peptide-1 receptor (GLP-1R) agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors, has been a focus because of its tissue-protective effects beyond lowering blood glucose levels 3) , such as cardiovascular protec-
Background
Individuals with diabetes mellitus have a greater risk of cardiovascular events than those without 1) . Patients with diabetes frequently experience restenosis after coronary angioplasty, even after intervention with currently available drug-eluting stents 2) . Consequently, the aim of glycemic control is not only the lowering of the blood glucose level but also improving the quality Copyright©2019 Japan Atherosclerosis Society This article is distributed under the terms of the latest version of CC BY-NC-SA defined by the Creative Commons Attribution License.
5% throughout the experimental period. Mice were divided into the saline-control (n 9) group, Ex-4 lowdose (300 pmol/kg body weight/day, n 10)-treated group, and Ex-4 high-dose (24 nmol/kg body weight/ day, n 10)-treated group. At 7 weeks of age, a miniosmotic pump (ALZEST, model 1004; DURECT, Cupertino, CA) was implanted under the skin of the back of each mouse after local anesthesia. Saline or Ex-4 (Sigma-Aldrich, Tokyo) was infused via the osmotic pump that continuously delivered the solution for up to 4 weeks. Endothelial denudation injuries were induced in the femoral artery at 8 weeks of age, followed by the evaluation of neointimal formation at 12 weeks of age.
Animals Fed High-Fat Diet
Seven-week-old male 129X1/SvJ mice were fed high-fat diet (20% protein, 20% carbohydrate, and 60% fat, D12492, Research Diet) and divided into the saline-control (n 5) group, Ex-4 low-dose (300 pmol/ kg body weight/day, n 5)-treated group, and Ex-4 high-dose (24 nmol/kg body weight/day, n 5)-treated group. Endothelial denudation injuries were induced in the femoral artery at 8 weeks of age. Mice were euthanized at 12 weeks of age and femoral arteries were isolated for tissue analysis.
Guidewire-Induced Endothelial Denudation Injury
Mouse femoral artery endothelial denudation injuries were established, as we previously reported 8, 11, 18) , in 129X1/SvJ mice treated as control (saline, n 9), Ex-4 low-dose (300 pmol/kg/day, n 10), and Ex-4 high-dose (24 nmol/kg/day, n 10) groups at 8 weeks of age, as described previously 8) . Briefly, endovascular injuries were induced by four passages of a 0.25-mm SilverSpeed-10 hydrophilic guidewire (Micro Therapeutics Inc., Irvine, CA, USA) into the left femoral artery. Mice were euthanized at 4 weeks after injury, and femoral arteries were isolated for tissue analysis.
Tissue Preparation and Morphometry
Following sacrifice, mice were perfused via a cannula in the left ventricle with phosphate-buffered saline for 5 min, followed by 4% paraformaldehyde for 30 min at 100 cm H2O. The femoral arteries were embedded in paraffin, cut into 5-µm sections, and prepared for Elastica van Gieson and immunofluorescence staining. Serial sections of the 0.5-mm proximal region from the incision site of the wire insertion were evaluated using Elastica van Gieson stain kit (ab150667, Abcam, Cambridge, UK) to visualize the internal elastic lamina, as described previously 11) . Specimens were viewed under a microscope (BZ9000; Keyence, Tokyo, Japan) connected to a computer. Intimal and metion 4) , anti-hepatic steatosis 5) , and anti-Alzheimer's disease 6) . Previously, we have reported the vascular-protective effects of the GLP-1R agonist Exendin-4 (Ex-4), including the attenuation of atheroma formation in apoE-deficient mice by inhibiting NF B activation in macrophages 7) and the reduction of neointima formation after vascular injury by inhibiting vascular smooth muscle cell (VSMC) proliferation 8) . Furthermore, we have recently demonstrated the anti-cancer effect of Ex-4 using a prostate cancer model 9, 10) . In addition, we reported that the DPP-4 inhibitor linagliptin attenuates neointima formation by not only incretin effects but also anti-oxidative stress effects 11) . The nuclear receptor superfamily has been recognized as one of key regulators of the inflammatory response and VSMC proliferation in atherosclerosis and vascular diseases 12) . Although much attention is focused on peroxisome proliferator-activated receptors (PPARs) 13) and liver X receptors (LXRs) 14) as therapeutic targets, we have investigated the role of NR4A orphan nuclear receptors, particularly NR4A3 neuronderived orphan receptor 1 (NOR1), in atherosclerosis and vascular diseases 15) . NOR1 was identified in primary cultured rat fetal forebrain cells undergoing apoptosis 16) . In human coronary arteries, NOR1 is expressed in VSMCs migrating into atherosclerotic lesions, but not in normal vessels, and mitogenic stimulation induces NOR1 expression via extracellular signal-regulated kinase (ERK)-mitogen-activated protein kinase (MAPK) and cAMP-responsive element-binding protein (CREB) phosphorylations 17) . NOR1 has a pivotal role in VSMC proliferation, and NOR1 deficiency reduces neointima formation after vascular injury by inhibiting G1 -S phase entry of cell cycle progression in VSMCs, as we reported previously 18, 19) . However, currently, there are no reports that have elucidated the interaction between GLP-1 and NOR1 in VSMCs. In the present study, we demonstrate that Ex-4 attenuates NOR1 expression both in vivo and in vitro in VSMCs.
Methods

Animals
The study protocol was reviewed and approved by the Animal Care and Use Committee of Fukuoka University. Six-week-old male 129X1/SvJ mice were purchased from Japan SLC, Inc. (Sizuoka, Japan). All mice were housed in a polycarbonate cage with a wooden chip mat on the floor, and water was available ad libitum. All mice were fed normal chow (20% protein, 70% carbohydrate, and 10% fat; D12450B, Research Diet, New Brunswick, NJ). The animal room was kept in a 12-h light/dark cycle at a constant temperature (22 1 ) and relative humidity of 55% Alexa Fluor 647 goat anti-rabbit IgG (A21246, Life technologies), and sections analyzed for PCNA were subsequently incubated with Alexa Fluor 488 donkey anti-goat IgG (A11055, Life technologies). Sections were counterstained with DAPI and visualized using confocal microscopy.
Insulin Measurements
Insulin concentrations in mouse serum were measured using Ultra-Sensitive Mouse Insulin ELISA Kit (Morinaga Institute of Biological Science, Inc. Kanagawa, Japan), according to the manufacturer's protocol.
Cell Culture
Human aortic smooth muscle cells were purchased from Lonza (Allendale, NJ) and maintained in dial areas were measured by computerized morphometry using BZ-II analyzer software (Keyence, Tokyo, Japan). Intimal hyperplasia was defined as neointimal layer formation medial to the internal elastic lamina. The medial area represents the area between external and internal elastic laminae. The intima-to-media ratio was calculated as the intimal area divided by the media area, as described previously 8, 11) .
Immunohistochemistry
Paraffin sections were incubated with a Cy-3-conjugated -smooth muscle actin antibody (C6198, SigmaAldrich). Serial sections were incubated with anti-NOR1 (HPA043360, Sigma-Aldrich) and anti-PCNA (sc-9857; Santa Cruz, CA) antibodies. Sections analyzed for NOR1 were subsequently incubated with Endothelial denudation injuries were induced in the left femoral artery of control (n 9) mice, Ex-4 low-dose (n 9)-treated mice, and Ex-4 high-dose (n 10)-treated mice. (A) Tissues were evaluated by staining with Elastica van Gieson to visualize the internal elastic lamina (magnification, 200). (B) The area of the intima, media, and intima/media was calculated for each group. One-way ANOVA was performed to calculate statistical significance. Data are mean SEM.
Signaling), mTOR (#2983; Cell Signaling), p27 Kip1 (#3686; Cell Signaling), and GAPDH (sc-20357; Santa Cruz).
Reverse Transcription (RT) and Quantitative RealTime PCR RT and quantitative real-time PCR were performed, as described previously 9, 10) . mRNA from human aortic SMCs was isolated using RNeasy Mini Kits (Qiagen, Venlo, the Netherlands) and reverse transcribed into cDNA. PCRs were performed using Light Cycler 2.0 (Roche, Basel, Switzerland) and SYBR Premix Ex Taq™ (Takara, Otsu, Japan). Each sample was analyzed in triplicate and normalized against TATA binding protein (TBP) mRNA expression. The following primer sequences were used: human TBP, 5´-TGCT-GCGGTAATCATGAGGATA-3´ (forward), 5´-TGA-AGTCCAAGAACTTAGCTGGAA-3´ (reverse); human NOR1, 5´-CCCCTCCAGGTTCCAGTTAT-3´ (forward), 5´-ATTTGGTACACGCAGGAAGG-3´ (reverse); human Skp2, 5´-ACACTGCAAAAGCCCA-GTTG-3´ (forward), 5´-TGCAGAATGAAGGCAAA-GGG-3´ (reverse). smooth muscle basal medium supplemented with 5% fetal bovine serum (FBS), hEGF, insulin, hFGF-B, and gentamicin/amphotericin-B (SmGM-2 SingleQuots; Lonza), as per the manufacturer's instructions, and rat aortic smooth muscle cells were purchased from Lonza and maintained in Dulbecco's modified Eagle medium supplemented with 10% FBS. Cells were grown to 60% -70% confluence, serum-deprived for at least 12 h, pretreated with 0.1 -10 nM Ex-4 or saline for 12 h, and stimulated with FBS at a final concentration of 10%. Cells were used between passages three and six for the experiments, and individual experiments were repeated at least three times with different preparations of cells.
Western Blot Analysis
Western blotting was performed, as described previously 9, 10) . The following primary antibodies were used: NOR1 (TA804872, ORIGENE), phosphop44/42 MAPK (Thr202/Tyr204) (#9101; Cell Signaling), p44/42 MAPK (#9102; Cell Signaling), phospho-CREB (Ser133) (#9198; Cell Signaling), CREB (#9197; Cell Signaling), phospho-Akt (Ser473) (#4058; Cell Signaling), Protein kinase B (Akt) (#9272; Cell Signaling), phospho-mTOR (Ser2448) (#2971; Cell Ohkura (Osaka University, Osaka, Japan).
Cell Cycle Analysis Using Flow Cytometry
Human aortic SMCs were seeded in 60-mm dishes at a density of 1 10 5 cells/ml. Cells were grown to 60% -70% confluence, serum-deprived for 36 h, pretreated with 10 nM Ex-4 or saline for 12 h, stimulated with FBS for 30 h. Cell cycle analysis was performed using Cycletest™ Plus DNA reagent kit (BD Biosciences), as per the manufacturer's instructions, and a BD FACSVerse (BD Biosciences, Franklin Lakes, NJ, USA). FlowJo (Tree Star, Inc., OR, USA) was used to analyze the flow cytometry data.
Statistical Analysis
Results are expressed as mean SEM. All statistical analyses were performed using GraphPad Prism
Plasmids, Transient Transfections, and Luciferase Assay
To evaluate NOR1 transcriptional activity, the luciferase reporter assay was performed in rat aortic SMCs (Lonza) transiently transfected with pGL3-MMTV or NOR1-LUC reporter constructs. Briefly, rat aortic SMCs were transfected for 24 h with 0.5 µg of reporter DNA using FuGENE HD Transfection Reagent (Roche). Next, cells were maintained under serum deprivation for 36 h, pretreated with or without 10 nM Ex-4 for 12 h, and then stimulated with FBS for 12 h. Luciferase activity was assayed using DualLuciferase Reporter Assay (Promega, Madison, WI, USA). Transfection efficiency was normalized to Renilla luciferase activity generated by co-transfection of cells with 10 ng/well pRL-SV40 (Promega). NOR1 promoter constructs were provided by Dr. Naganari all groups, and neointima formation was evaluated at 12 weeks of age. Endothelial denudation injury in control mice resulted in considerable neointima formation. As depicted in Fig. 1A , elastic staining revealed the reduction of neointima formation after vascular injury. Quantitative analysis by measuring squares of the intima, media, and intima-to-media (I/M) ratio suggested that Ex-4 reduced neointima formation after vascular injury in a dose-dependent manner (Fig. 1B) . However, statistical significances were not achieved ( Table 1) . As shown in Table 2 , although high-dose Ex-4 significantly decreased mouse body weight, the blood glucose level and serum insulin concentration software (version 7.0; GraphPad Software, SD, USA). Unpaired t -tests and one-or two-way ANOVA were performed for statistical analysis, as appropriate. Pvalues 0.05 were considered statistically significant.
Results
Exendin-4 Attenuates Neointima Formation After Vascular Injury in Non-Diabetic Mice
129X1/SvJ mice were treated with the control (saline), low-dose Ex-4, or high-dose Ex-4 from 7 to 12 weeks of age. Mouse femoral artery endothelial denudation injuries were established at 8 weeks of age in in the intima and media areas. As shown in Fig. 2B , Ex-4 decreased the cell number in the neointima and the I/M ratio in a dose-dependent manner. Compared with the control, significant reduction in the cell number was achieved in the high-dose Ex-4 group. To further examine whether Ex-4 decreased NOR1 expression in migrating VSMCs after vascular injury, we next conducted NOR1 immunohistochemistry using injured mouse vessels. As depicted in Fig. 2C , profound NOR1 expression with nuclear localization was detected in non-Ex-4-treated control vessels. However, NOR1 expression was dramatically decreased in Ex-4-treated mouse vessels. Finding NOR1-positive cells in the neointima suggested that Ex-4 significantly and were not changed by Ex-4 treatment because the mice were not diabetic, suggesting that the reduction of neointima formation by Ex-4 was independent of the Ex-4 effect on glucose metabolism.
Exendin-4 Decreases VSMC Proliferation and NOR1 Expression in the Neointima
To confirm that cells occupying the neointima after vascular injury were VSMCs, we next performed immunohistochemistry using VSMC marker -smooth muscle cell actin. As depicted in Fig. 2 , all cells located in the neointima were VSMC ( Fig. 2A) in all groups. To examine whether Ex-4 decreased the number of cells occupying neointima formation, we counted cells Serum-deprived human aortic SMCs were preincubated with vehicle or 10 nM Ex-4 for 12 h and stimulated with 10% FBS for 15 min. Whole cell lysates were analyzed for phosphorylated p44/42 MAPK (A) and Ser-133-phosphorylated CREB (B). Cohybridization for total p44/42 MAPK and total CREB was used as control. Statistical significance was calculated using unpaired t -tests. Data are mean SEM. P 0.05 vs. FBS( ) Ex-4( ). (C) Serum-deprived human aortic SMCs were preincubated with vehicle or 10 nM Ex-4 for 12 h and stimulated with 10% FBS for the indicated times. Whole cell lysates were analyzed for phosphorylated Akt and mTOR. Two-way ANOVA was performed to calculate statistical significance. Data are mean SEM. P 0.05 vs. FBS( ) 30 min Ex-4( ). mouse 18) VSMCs, NOR1 expression was also negligible in serum-deprived quiescent human VSMCs, and serum stimulation dramatically and promptly induced NOR1 protein (Fig. 3A) and mRNA (Fig. 3B) expression. Interestingly, after pretreatment with Ex-4, serum-induced NOR1 expression was significantly decreased in a dose-dependent manner (Fig. 3A, B) . To elucidate whether Ex-4 decreased NOR1 expression by inhibiting NOR1 promoter activity, we next conducted a luciferase assay using NOR1 promoter-Luc construct transfected into rat VSMCs. As shown in Fig. 3C shows, serum-induced NOR1 promoter activity was significantly reduced by 10 nM Ex-4 pretreatment, suggesting that Ex-4 decreased NOR1 expresdose-dependently decreased NOR1-positive VSMCs (Fig. 2D) . Interestingly, in parallel with the reduction of NOR1 expression by Ex-4 in VSMCs, Ex-4 significantly and dose-dependently decreased cell proliferation marker PCNA-positive cells (Fig. 2C, E) . These data suggest that Ex-4 decreased proliferating VSMCs in the neointima after vascular injury, which was associated with the reduction of NOR1 expression in vivo.
Exendin-4 Decreases Serum-Induced NOR1 Expression Via GLP-1R
Next, we examined whether Ex-4 inhibited NOR1 expression in vitro using primary cultured VSMCs. Compatible with our previous reports using rat 17) and Table 3 ), suggesting that Ex-4 inhibits VSMC proliferation by attenuating cell cycle progression. Next, we examined whether Ex-4 regulated cell cycle regulators.
As shown in Fig. 4C , serum-induced degradation of p27 Kip, a major negative regulator of G1 -S phase entry, was significantly inhibited by Ex-4 treatment. In addition, S-phase kinase-associated protein 2 (Skp2), which is the ubiquitin ligase of p27 Kip, was induced by serum stimulation and resulted in p27 kip degradation. Interestingly, Ex-4 significantly decreased Skp2 gene expression after serum stimulation (Fig. 5D ).
Exendin-4 Attenuates Neointima Formation After Vascular Injury in Diabetic Mice
Because Ex-4 is used as a medication for patients with type 2 diabetes mellitus (T2DM), we next examined whether Ex-4 decreased neointima formation after vascular injury in mice fed high-fat diet, a model for insulin-resistant T2DM. As depicted in Fig. 6A , elastic staining revealed the reduction of neointima formation after vascular injury. Quantitative analysis by measuring squares of the intima, media, and I/M ratio suggested that Ex-4 reduced neointima formation after vascular injury in a dose-dependent manner (Fig. 6B) . However, statistical significance was not observed ( Table 4) . As shown in Table 5 , body weight and the plasma glucose level were significantly decreased by Ex-4 in a dose-dependent manner, suggesting that Ex-4 affected glucose metabolism.
Following experiments using non-diabetic normal mice, we counted cells in the neointima and media areas. As shown in Fig. 7A shows, the neointima was completely occupied by VSMCs, and the cell number in the neointima and I/M ratio were decreased dose-dependently, although statistical significance was not observed. For further investigation, we performed immunohistochemistry of NOR1 and PCNA. As shown in Fig. 7C , Ex-4 decreased NOR1 expression and PCNA-positive proliferating cells. Furthermore, cell counting revealed that the Ex-4-induced reductions of sion by inhibiting NOR1 promoter activity. However, the canonical pathway of GLP-1R is mediated via cAMP-protein kinase A (PKA) activation. As shown in Fig. 3D , co-incubation with GLP-1R antagonist Exendin 9-39 (Ex9-39) and PKA inhibitor PKI cancelled the reduction of NOR1 gene expression by Ex-4. These data suggest that Ex-4 decreased serum-induced NOR1 promoter activation and gene expression via GLP-1R activation and its downstream canonical signaling pathway.
Exendin-4 Inhibits Serum-Induced ERK-MAPK and CREB Phosphorylations
In our previous report, mitogenic stimulation induced NOR1 expression via ERK-MAPK and CREB phosphorylations 17) . Next, we examined the effect of Ex-4 on ERK-MAPK and CREB phosphorylations in human VSMCs by western blotting. As shown in Fig. 4A , pretreatment with 10 nM Ex-4 significantly decreased serum-induced phosphorylation of ERK-MAPK. Furthermore, serum-induced CREB phosphorylation was decreased by Ex-4 pretreatment (Fig. 4B) . These data suggest that Ex-4 decreased NOR1 expression via the inhibition of ERK-MAPK-CREB signals in VSMCs. In addition, we examined other VSMC growth signals, protein kinase B (Akt) and mammalian target of rapamycin (mTOR). As shown in Fig. 4C , Ex-4 did not attenuate serum-induced Akt phosphorylation. However, small but significant attenuation of serum-induced mTOR phosphorylation was observed after Ex-4 treatment (Fig. 4C) .
Exendin-4 Attenuates Cell Cycle Progression in VSMCs
Because NOR1 regulates VSMC proliferation by accelerating G1 -S phase during cell cycle progression, as we reported previously 18) , we next examined whether Ex-4 attenuates cell cycle progression in human VSMCs. As shown in Fig. 5 , G1 -S phase and G2/M phase were induced by serum stimulation in human VSMCs. Furthermore, 10 nM Ex-4 pretreatment significantly at- expression, resulting in inhibition of cell cycle progression. As we reported previously 7, 8) , the direct vascularprotective effect of incretin has been a recent focus. Reports from other groups confirmed the hypothesis that incretins, particularly GLP-1, may have direct anti-atherosclerotic and vascular-protective effects independent of their glucose-lowering effect 20, 21) . Furthermore, current evidence based on large scale clinical trials in patients with type 2 diabetes using GLP-1R agonists suggest vascular-protective effects of GLP-1 in animal models as well as patients with type 2 diabetes 22, 23) . VSMC proliferation contributes to not only primary atherosclerotic lesions but also vascular stenosis after vascular injury and coronary angioplasty. In addition, several pathological backgrounds in the dia-NOR1 expression and PCNA-positive proliferating cells were significant and dose dependent (Fig. 7D, E) . These data suggested that Ex-4 decreased NOR1 expression and VSMC proliferation in vivo, even in diabetic model mice.
Discussion
The present study suggested that GLP-1R agonist Ex-4 attenuates neointima formation after vascular injury and VSMC proliferation associated with the reduction of NOR1 expression in both diabetic and non-diabetic model mice. Furthermore, the molecular mechanism by which Ex-4 attenuates VSMC proliferation was the reduction of serum-induced Skp2 gene lated via epigenetic modification 30) and microRNA-638 expression 31) . Furthermore, NOR1 phosphorylation by DNA-dependent protein kinase reportedly modulates VSMC proliferation 32) . Despite several known regulation mechanisms of NOR1 expression and its activation, there has been no report suggesting NOR1 regulation in VSMCs by clinical medications, such as antihypertensive drugs, anti-diabetic agents, and anticoagulants. This is the first report suggesting that an antidiabetic agent and a GLP-1R agonist, attenuates NOR1 expression in VSMCs. In our previous reports using mouse VSMCs, we investigated two main targets of NOR1 that accelerate VSMC proliferation: Cyclin D1 18) and Skp2 19) . In the present study using human VSMCs, Cyclin D1 expression was not changed by Ex-4-induced NOR1 reduction (data not shown). However, Skp2 gene expression was significantly decreased (Fig. 5D) , resulting in the upregulation of p27 Kip protein expression (Fig. 5C ) and attenuation of cell cycle progression (Fig. 5A, B) . These data suggest that the main target of NOR1 related to cell cycle progression is Skp2 in human VSMCs.
In the present study, we found that Ex-4 inhibited serum-induced ERK-MAPK phosphorylation (Fig. 4A) . Interestingly, we previously reported the same Ex-4 efbetic state may accelerate VSMC pathogenesis directly and indirectly 24) . Therefore, the inhibition of smooth muscle cell proliferation by anti-diabetic agents could be beneficial to patients with type 2 diabetes. Among vascular cells, VSMCs abundantly express GLP-1R 8, 21) and important targets for vascular-protective effects by GLP-1. A GLP-1R agonist attenuates neointima formation after vascular injury 8, 21) , which has a direct effect on VSMCs but not the activation of re-endothelialization after endothelial denudation 25) , suggesting that the vascular-protective effect of GLP-1 mainly occurs in VSMCs. Some mechanisms by which GLP-1 attenuates VSMC pathogenesis have been reported, such as inhibition of RAS-related C3 botulinus toxin substrate 1 (Rac1) activation 26) and enhancement of endoplasmic reticulum-mitochondria coupling 27) . Furthermore, some data suggest that adiponectin is a molecular target through which incretin protects against vascular diseases 28, 29) . In addition to these mechanisms, we provide a novel mechanism by which GLP-1 attenuates NOR1 expression in VSMCs in the present study.
NOR1 is a well-elucidated orphan nuclear receptor that regulates VSMC proliferation 15) . A recent study suggested that NOR1 expression in VSMCs is regu- randomized control trial using Exenatide, the EXS-CEL study, could not demonstrate significant reduction compared with the placebo control 35) , although other GLP-1R agonists did improve cardiovascular outcome 22, 23) . The EXSCEL study has a shorter study period and higher baseline HbA1c than the LEADER trial using liraglutide 22) (3.8 years vs. 3.2 years and 8.0% vs. 8.7%, respectively). In addition, sulfonylureas and insulin use were profoundly increased in the placebo group of the LEADER trial, although GLP-R agonists, sodium-glucose cotransporter 2 inhibitors, and DPP-4 inhibitors use were increased in the placebo group of the EXSCEL trial 35) . These clinical differences may contribute to the different cardiovascular outcomes between the LEADER trial and EXSCEL study. In fact, the low dose of Ex-4 in the present study is the pharmacological dose, as discussed in our previous fect in the prostate cancer cell line LNCaP 9) . Both VSMCs and cancer cells are pathologically proliferating and growing cells. Ex-4 may regulate pathological cell proliferation and growth as a tissue-protective effect. In the present study, we investigated Ex-4 actions in VSMCs. However, the main clinical target of Ex-4 as an incretin therapy for patients with type 2 diabetes is pancreatic cells to stimulate glucose-dependent insulin secretion 33) . Interestingly, a report has suggested an interaction between incretin and NOR1 in pancreatic cells 34) . Therefore, further elucidation of the interaction between incretin and NOR1 is required.
In the present study, all our experiments were conducted using Ex-4 as a GLP-1R agonist, which is clinically available as Exenatide. Although the present study and our previous studies 7, 8) demonstrated the vascular-protective effect of Ex-4, a recent large scale racy of data analysis. reports 7, 9, 36) , suggesting that some beneficial clinical cardiovascular effect could be expected from the present study. However, different individual effects on cardiovascular systems by GLP-1R agonists are also suggested 37) . Further clinical trials and basic experiments are required.
Conclusion
Ex-4 attenuates neointima formation after vascular injury and VSMC proliferation possibly by inhibiting NOR1 and Skp2 expression. In addition, Ex-4 attenuates ERK-MAPK and CREB phosphorylations as well as G1 -S phase entry during cell cycle progression in VSMCs. The reduction of NOR1 expression could be key in preventing cardiovascular events and atherosclerosis in patients with type 2 diabetes using incretin therapy.
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